EXACT Sciences Corporation (EXAS) Announces Published Study Results for the Company’s Colorectal Cancer Detection Technology
EXACT Sciences Corporation (NASDAQ: EXAS), a research and development company focused on developing non-invasive screening technologies for early detection of colorectal cancer, recently announced published results of a comprehensive colorectal cancer detection study in which stool and blood plasma were individually assessed to determine which type of testing was more accurate in detecting the disease. The study results showed 92 percent sensitivity for detecting colorectal cancer in stool samples. Utilizing state-of-the-art BEAMing DNA detection technology from Johns Hopkins University, the study results showed that stool-based DNA testing outperformed blood plasma testing, especially for the detection of early-stage colorectal cancers. According…